.png){kind=logo}
Stock image for illustration purposes only - book cover, edition or condition may vary.
Risk/benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents
. Ed(S): Morganroth, Joel; Moore, E. Neil
€ 249.54
FREE Delivery in Ireland
Description for Risk/benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents
Paperback. Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 and 28, 1988 Editor(s): Morganroth, Joel; Moore, E. Neil. Series: Developments in Cardiovascular Medicine. Num Pages: 298 pages, biography. BIC Classification: MJD. Category: (G) General (US: Trade). Dimension: 235 x 155 x 17. Weight in Grams: 492.
The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of ... Read more
The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of ... Read more
Product Details
Format
Paperback
Publication date
2011
Publisher
Springer-Verlag New York Inc. United States
Number of pages
298
Condition
New
Series
Developments in Cardiovascular Medicine
Number of Pages
298
Place of Publication
New York, NY, United States
ISBN
9781461288886
SKU
V9781461288886
Shipping Time
Usually ships in 15 to 20 working days
Ref
99-15
Reviews for Risk/benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents